LabGenomics (084650) Fundamentals 2026 — Revenue Analysis | SniperIQ
LabGenomics (084650) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩47.5B, trading at ₩640.00 on the KOE. This SniperIQ fundamentals page covers LabGenomics's valuation, profitability (net margin -75.7%), revenue (₩88.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is LabGenomics's market cap?
LabGenomics (084650) has a market capitalization of approximately ₩47.5B, trading at ₩640.00 on the KOE. Market cap moves with the live share price.
What is LabGenomics's P/E ratio?
LabGenomics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is LabGenomics?
LabGenomics runs a net profit margin of -75.7%, a gross margin of 23.4%, and an operating margin of -63.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does LabGenomics generate?
LabGenomics reported revenue of ₩88.2B for fiscal year 2025, with net income of -₩64.4B and earnings per share (EPS) of -867.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does LabGenomics pay a dividend?
LabGenomics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is LabGenomics financially healthy?
LabGenomics carries a debt-to-equity ratio of 0.41x and a current ratio of 1.17x, with a market beta of -0.07. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is LabGenomics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For LabGenomics (084650) the key facts are: market cap ₩47.5B, revenue ₩88.2B, 52-week range 621-2585. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track LabGenomics's full fundamentals live
Get LabGenomics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.